


## Correspondence: Image Gallery

# Pityriasis rosea-like eruption after Pfizer–BioNTech COVID-19 vaccination

DOI: 10.1111/bjd.20143



A 35-year-old male presented with an extremely itchy exanthem after Pfizer–BioNTech COVID-19 vaccination.<sup>1</sup> A single oval erythematous lesion appeared on the thigh after the first dose (a) and progressed insidiously to a papulosquamous rash on the trunk and proximal extremities (b). After the second dose, it notably flared up (c). Serological evaluation for human herpesvirus reactivation was negative. Pityriasis rosea-like eruption was diagnosed.<sup>2</sup> Antihistamines and topical betamethasone were initiated, with clinical improvement after 2 weeks. Considering that immunization programmes are being conducted worldwide, it is important to increase awareness within the medical community, so that appropriate management be provided.

A.M. Carballido Vázquez <sup>1</sup> and B. Morgado<sup>2,3</sup>

<sup>1</sup>Department of Dermatology, University Hospital of Valladolid, Valladolid, Spain; <sup>2</sup>Faculty of Medicine and Biomedical Sciences, University of Algarve,

Faro, Portugal; and <sup>3</sup>Hospital Center of Vila Nova de Gaia/Espinho, Vila Nova de Gaia, Portugal  
Email: anamcv@gmail.com

## References

- 1 Polack FP, Thomas SJ, Kitchin N et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. *N Engl J Med* 2020; **383**:2603–15.
- 2 Drago F, Ciccarese G, Parodi A. Pityriasis rosea and pityriasis rosea-like eruptions: how to distinguish them? *JAAD Case Rep* 2018; **4**:800–1.

Funding sources: none.

Conflicts of interest: none to declare.